TECHNOLOGY: Cell therapy
HSPCs derived from iPS cells and engineered to express the MLL-AF4 fusion oncogene could improve the engraftment of HSPC transplant therapies. The HSPCs were generated by inducing differentiation of iPS cells from healthy volunteers, then transfecting the cells with an MLL-AF4 plasmid to enhance their...